Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64.5M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
32M
-
Shares change
-
+3.01M
-
Total reported value, excl. options
-
$183M
-
Value change
-
+$30.2M
-
Put/Call ratio
-
2.22
-
Number of buys
-
35
-
Number of sells
-
-10
-
Price
-
$5.73
Significant Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q1 2023
58 filings reported holding INZY - Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share as of Q1 2023.
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32M shares
of 64.5M outstanding shares and own 49.53% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (4.27M shares), Sofinnova Investments, Inc. (3.66M shares), Deep Track Capital, LP (3.25M shares), Rock Springs Capital Management LP (3.21M shares), Pivotal bioVenture Partners Investment Advisor LLC (3.21M shares), NEA Management Company, LLC (2.44M shares), SPHERA FUNDS MANAGEMENT LTD. (1.78M shares), MILLENNIUM MANAGEMENT LLC (1.69M shares), CHI Advisors LLC (1.34M shares), and VANGUARD GROUP INC (1.33M shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.